D'Erme Angelo Massimiliano, Romanelli Marco, Chiricozzi Andrea
Dermatology Unit, Livorno Hospital, Livorno.
Dermatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Drug Des Devel Ther. 2017 May 15;11:1473-1480. doi: 10.2147/DDDT.S113192. eCollection 2017.
Atopic dermatitis (AD) is among the most common inflammatory skin diseases in children and adults in industrialized countries. Up to one-third of adults (probably a smaller proportion in childhood) suffer from moderate-to-severe AD, whose recommended treatment is usually based on systemic therapies. The currently available therapeutics are limited, and AD management becomes challenging in most cases. Over the last few years, new advances in the understanding of AD pathogenic mechanisms and inflammatory pathways have led to the identification of specific therapeutic targets and new molecules have been tested. Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor α subunit that is able to block the signaling of both IL-4 and IL-13 and achieve rapid and significant improvements in adults with moderate-to-severe AD. Dupilumab is ready to inaugurate a long and promising biological target treatment option for Th2 cell-mediated atopic immune response that characterizes AD.
特应性皮炎（AD）是工业化国家儿童和成人中最常见的炎症性皮肤病之一。高达三分之一的成年人（儿童中比例可能较小）患有中度至重度AD，其推荐治疗通常基于全身疗法。目前可用的治疗方法有限，在大多数情况下，AD的管理具有挑战性。在过去几年中，对AD致病机制和炎症途径的新认识导致了特定治疗靶点的确定，并对新分子进行了测试。度普利尤单抗是一种完全人源化单克隆抗体，靶向白细胞介素-4受体α亚基，能够阻断白细胞介素-4和白细胞介素-13的信号传导，并在中度至重度AD成人患者中实现快速且显著的改善。度普利尤单抗即将开启针对以Th2细胞介导的特应性免疫反应为特征的AD的漫长且有前景的生物靶向治疗选择。
